Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A. Ramos TC, et al. Among authors: ramos m. Cancer Biol Ther. 2006 Apr;5(4):375-9. doi: 10.4161/cbt.5.4.2522. Epub 2006 Apr 19. Cancer Biol Ther. 2006. PMID: 16575203 Clinical Trial.
Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YÁ, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB, Ramos TC. Ramos-Suzarte M, et al. Among authors: ramos tc. Cancer Biol Ther. 2012 Jun;13(8):600-5. doi: 10.4161/cbt.19849. Epub 2012 Jun 1. Cancer Biol Ther. 2012. PMID: 22555809 Clinical Trial.
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.
Londres HD, Armada JJ, Martínez AH, Abdo Cuza AA, Sánchez YH, Rodríguez AG, Figueroa SS, Llanez Gregorich EM, Torres Lahera ML, Peire FG, González TM, González YZ, Añé Kouri AL, Palomo AG, Concepción MT, Pérez LM, Luaces-Alvarez PL, Iglesias DE, Hernández DS, Suzarte MR, Ramos TC. Londres HD, et al. Among authors: ramos tc. Immunotherapy. 2022 May;14(7):521-530. doi: 10.2217/imt-2022-0027. Epub 2022 Mar 21. Immunotherapy. 2022. PMID: 35306855 Free PMC article. Clinical Trial.
Nimotuzumab for COVID-19: case series.
Abdo Cuza AA, Ávila JP, Martínez RM, González JJ, Aspuro GP, Gutiérrez Martínez JA, Suzarte MR, Hernández DS, Añé-Kouri AL, Ramos TC. Abdo Cuza AA, et al. Among authors: ramos tc. Immunotherapy. 2021 Nov 22:10.2217/imt-2021-0269. doi: 10.2217/imt-2021-0269. Online ahead of print. Immunotherapy. 2021. PMID: 34806405 Free PMC article.
Spatio-temporal analysis of American Tegumentary Leishmaniasis incidences in the Brazilian state of Amazonas: 2011 to 2022.
Chagas ÉCDS, Ferreira FADS, Mwangi VI, Terrazas WCM, Becker JN, Simões RC, Pacífico EMSS, Silva ASD, Marques CDS, Chagas ECDS, Machado MB, Figueira EAG, Castro DB, Ramos TCA, Oliveira JH. Chagas ÉCDS, et al. Among authors: ramos tca. Acta Trop. 2024 May 19;256:107266. doi: 10.1016/j.actatropica.2024.107266. Online ahead of print. Acta Trop. 2024. PMID: 38772433
Multiple introductions and country-wide spread of DENV-2 genotype II (Cosmopolitan) in Brazil.
Gräf T, Ferreira CDN, de Lima GB, de Lima RE, Machado LC, Campos TL, Schemberger MO, Faoro H, Paiva MHS, Bezerra MF, Nascimento V, Souza V, Nascimento F, Mejía M, Silva D, de Oliveira YS, Gonçalves L, Ramos TCA, de Castro DB, Arcanjo AR, Dantas HAP, Presibella MM, Fernandes SB, Gregianini TS, Paz E Silva KM, Sacchi CT, Cruz ACR, Duarte Dos Santos CN, Bispo de Filippis AM, Bello G, Wallau GL, Salvato RS, Naveca F. Gräf T, et al. Among authors: ramos tca. Virus Evol. 2023 Sep 28;9(2):vead059. doi: 10.1093/ve/vead059. eCollection 2023. Virus Evol. 2023. PMID: 38288387 Free PMC article.
34 results